Related references
Note: Only part of the references are listed.Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia
C. Zwick et al.
ANNALS OF ONCOLOGY (2011)
The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
Manfred Ahlgrimm et al.
BLOOD (2011)
The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase
Nimish N. Vachharajani et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Rituximab A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Gillian M. Keating
DRUGS (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma
Helene Blasco et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2009)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
Pharmacokinetics of rituximab and its clinical use: Thought for the best use?
Guillaume Cartron et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Pharmacokinetic behavior of rituximab - A study of different schedules of administration for heterogeneous clinical settings
MB Regazzi et al.
THERAPEUTIC DRUG MONITORING (2005)
Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK
P Jilma-Stohlawetz et al.
TRANSFUSION AND APHERESIS SCIENCE (2005)
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma:: results of a multicenter phase II study
A Josting et al.
ANNALS OF ONCOLOGY (2005)
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
CM Ng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys
M Tokar et al.
LEUKEMIA & LYMPHOMA (2004)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:: results of the NHL-B2 trial of the DSHNHL
M Pfreundschuh et al.
BLOOD (2004)
Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis c virus-related liver cirrhosis
T Takao et al.
AMERICAN JOURNAL OF HEMATOLOGY (2004)
Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
K Tobinai et al.
ANNALS OF ONCOLOGY (2004)
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation
J Mangel et al.
ANNALS OF ONCOLOGY (2003)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study
I Iacona et al.
THERAPEUTIC DRUG MONITORING (2000)
Share Paper
